Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 1/2019

19.12.2018

Familial hyperaldosteronism type III a novel case and review of literature

verfasst von: Natividad Pons Fernández, Francisca Moreno, Julia Morata, Ana Moriano, Sara León, Carmen De Mingo, Ángel Zuñiga, Fernando Calvo

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Less than 15% of hypertension cases in children are secondary to a primary hyperaldosteronism. This is idiopathic in 60% of the cases, secondary to a unilateral adenoma in 30% and 10% remaining by primary adrenal hyperplasia, familial hyperaldosteronism, ectopic aldosterone production or adrenocortical carcinoma.To date, four types of familial hyperaldosteronism (FH I to FH IV) have been reported. FH III is caused by germline mutations in KCNJ5, encoding the potassium channel Kir3.4. The mutations cause the channel to lose its selectivity for potassium, allowing large quantities of sodium to enter the cell. As a consequence, the membrane depolarizes, voltage-gated calcium channels open, calcium enters the cell, initiating the cascade that leads to aldosterone synthesis. Somatic mutations in KCNJ5 has also been described in aldosterone-producing adenomas. The most frequent presentation of FH III is with severe hyperaldosteronism symptoms and resistance to pharmacological therapy which leads to bilateral adrenalectomy. We will review current literature and describe a child with FH III due to a novel de novo deletion in KCNJ5 with wild phenotype as a sign of clinical variability of this disease.
Literatur
1.
Zurück zum Zitat Thomas RM, Ruel E, Shantavasinkul PC, Corsino L. Endocrine hypertension: an overview on the current etiopathogenesis and management options. World J Hypertens. 2015;5:14–27.CrossRefPubMedPubMedCentral Thomas RM, Ruel E, Shantavasinkul PC, Corsino L. Endocrine hypertension: an overview on the current etiopathogenesis and management options. World J Hypertens. 2015;5:14–27.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–5.CrossRefPubMed Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–5.CrossRefPubMed
4.
Zurück zum Zitat Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G, et al. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab. 2012;97:881–9.CrossRefPubMed Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G, et al. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab. 2012;97:881–9.CrossRefPubMed
5.
Zurück zum Zitat Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (primary Aldosteronism in TOrino-GENetic forms). Hypertension. 2011;58:797–803.CrossRefPubMed Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (primary Aldosteronism in TOrino-GENetic forms). Hypertension. 2011;58:797–803.CrossRefPubMed
6.
Zurück zum Zitat Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. https://doi.org/10.1210/jc.2015-4061. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. https://​doi.​org/​10.​1210/​jc.​2015-4061.
7.
Zurück zum Zitat Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol. 1991;18:283–6.CrossRefPubMed Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol. 1991;18:283–6.CrossRefPubMed
8.
Zurück zum Zitat Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens. 2008;26:1577–82.CrossRefPubMed Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens. 2008;26:1577–82.CrossRefPubMed
9.
Zurück zum Zitat Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117–23.CrossRefPubMedPubMedCentral Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117–23.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–72.CrossRefPubMedPubMedCentral Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–72.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, et al. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2013;98:E1861–5.CrossRefPubMedPubMedCentral Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, et al. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2013;98:E1861–5.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Monticone S, Bandulik S, Stindl J, Zilbermint M, Dedov I, Mulatero P, et al. A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue. J Clin Endocrinol Metab. 2015;100:E114–8.CrossRefPubMed Monticone S, Bandulik S, Stindl J, Zilbermint M, Dedov I, Mulatero P, et al. A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue. J Clin Endocrinol Metab. 2015;100:E114–8.CrossRefPubMed
13.
Zurück zum Zitat Galati SJ, Hopkins SM, Cheesman KC, Zhuk RA, Levine AC. Primary aldosteronism: emerging trends. Trends Endocrinol Metab. 2013;24:421–30.CrossRefPubMed Galati SJ, Hopkins SM, Cheesman KC, Zhuk RA, Levine AC. Primary aldosteronism: emerging trends. Trends Endocrinol Metab. 2013;24:421–30.CrossRefPubMed
14.
Zurück zum Zitat Monticone S, Tetti M, Burrello J, Buffolo F, de Giovanni R, Veglio F, et al. Familial hyperaldosteronism type III. J Hum Hypertens. 2017;31:776–81.CrossRefPubMed Monticone S, Tetti M, Burrello J, Buffolo F, de Giovanni R, Veglio F, et al. Familial hyperaldosteronism type III. J Hum Hypertens. 2017;31:776–81.CrossRefPubMed
15.
Zurück zum Zitat Scholl UI, Stolting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4:e06315.CrossRefPubMedPubMedCentral Scholl UI, Stolting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4:e06315.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Monticone S, Buffolo F, Tetti M, Veglio F, Pasini B, Mulatero P. Genetics in endocrinology: the expanding genetic horizon of primary aldosteronism. Eur J Endocrinol. 2018;178:R101–11.CrossRefPubMed Monticone S, Buffolo F, Tetti M, Veglio F, Pasini B, Mulatero P. Genetics in endocrinology: the expanding genetic horizon of primary aldosteronism. Eur J Endocrinol. 2018;178:R101–11.CrossRefPubMed
17.
Zurück zum Zitat Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension. 2014;64:354–61.CrossRefPubMed Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension. 2014;64:354–61.CrossRefPubMed
18.
Zurück zum Zitat Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81.CrossRefPubMed Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81.CrossRefPubMed
19.
Zurück zum Zitat Douillard C, Houillier P, Nussberger J, Girerd X. SFE/SFHTA/AFCE consensus on primary Aldosteronism, part 2: first diagnostic steps. Ann Endocrinol (Paris). 2016;77:192–201.CrossRef Douillard C, Houillier P, Nussberger J, Girerd X. SFE/SFHTA/AFCE consensus on primary Aldosteronism, part 2: first diagnostic steps. Ann Endocrinol (Paris). 2016;77:192–201.CrossRef
20.
Zurück zum Zitat Martinez-Aguayo A, Aglony M, Campino C, Garcia H, Bancalari R, Bolte L, et al. Aldosterone, plasma renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population. Hypertension. 2010;56:391–6.CrossRefPubMed Martinez-Aguayo A, Aglony M, Campino C, Garcia H, Bancalari R, Bolte L, et al. Aldosterone, plasma renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population. Hypertension. 2010;56:391–6.CrossRefPubMed
21.
Zurück zum Zitat Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, et al. SFE/SFHTA/AFCE primary aldosteronism consensus: introduction and handbook. Ann Endocrinol (Paris). 2016;77:179–86.CrossRef Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, et al. SFE/SFHTA/AFCE primary aldosteronism consensus: introduction and handbook. Ann Endocrinol (Paris). 2016;77:179–86.CrossRef
22.
Zurück zum Zitat Reznik Y, Amar L, Tabarin A. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: confirmatory testing. Ann Endocrinol (Paris). 2016;77:202–7.CrossRef Reznik Y, Amar L, Tabarin A. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: confirmatory testing. Ann Endocrinol (Paris). 2016;77:202–7.CrossRef
23.
Zurück zum Zitat Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, Kudo M, et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension. 2015;65:1096–102.CrossRefPubMed Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, Kudo M, et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension. 2015;65:1096–102.CrossRefPubMed
24.
Zurück zum Zitat Crudo V, Monticone S, Burrello J, Buffolo F, Tetti M, Veglio F, et al. Hyperaldosteronism: how to discriminate among different disease forms? High Blood Press Cardiovasc Prev. 2016;23:203–8.CrossRefPubMed Crudo V, Monticone S, Burrello J, Buffolo F, Tetti M, Veglio F, et al. Hyperaldosteronism: how to discriminate among different disease forms? High Blood Press Cardiovasc Prev. 2016;23:203–8.CrossRefPubMed
25.
Zurück zum Zitat Bardet S, Chamontin B, Douillard C, Pagny JY, Hernigou A, Joffre F, et al. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: subtype diagnosis. Ann Endocrinol (Paris). 2016;77:208–13.CrossRef Bardet S, Chamontin B, Douillard C, Pagny JY, Hernigou A, Joffre F, et al. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: subtype diagnosis. Ann Endocrinol (Paris). 2016;77:208–13.CrossRef
26.
Zurück zum Zitat Rossi GP, Auchus RJ, Brown M, Lenders JWM, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151–60.CrossRefPubMed Rossi GP, Auchus RJ, Brown M, Lenders JWM, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151–60.CrossRefPubMed
27.
Zurück zum Zitat Pérez AJ, Casal M, Courel MA, Andrade MA. Hiperaldosteronismo primario: aspectos diagnósticos y terapéuticos. Hipertension y Riesgo Vascular. 2002;19:70–9. Pérez AJ, Casal M, Courel MA, Andrade MA. Hiperaldosteronismo primario: aspectos diagnósticos y terapéuticos. Hipertension y Riesgo Vascular. 2002;19:70–9.
28.
Zurück zum Zitat Zennaro MC, Jeunemaitre X. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: genetic diagnosis of primary aldosteronism. Ann Endocrinol (Paris). 2016;77:214–9.CrossRef Zennaro MC, Jeunemaitre X. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: genetic diagnosis of primary aldosteronism. Ann Endocrinol (Paris). 2016;77:214–9.CrossRef
29.
Zurück zum Zitat Adachi M, Muroya K, Asakura Y, Sugiyama K, Homma K, Hasegawa T. Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature. Horm Res Paediatr. 2014;82:138–42.CrossRefPubMed Adachi M, Muroya K, Asakura Y, Sugiyama K, Homma K, Hasegawa T. Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature. Horm Res Paediatr. 2014;82:138–42.CrossRefPubMed
30.
Zurück zum Zitat Tong A, Liu G, Wang F, Jiang J, Yan Z, Zhang D, et al. A novel phenotype of familial hyperaldosteronism type III: concurrence of Aldosteronism and Cushing's syndrome. J Clin Endocrinol Metab. 2016;101:4290–7.CrossRefPubMedPubMedCentral Tong A, Liu G, Wang F, Jiang J, Yan Z, Zhang D, et al. A novel phenotype of familial hyperaldosteronism type III: concurrence of Aldosteronism and Cushing's syndrome. J Clin Endocrinol Metab. 2016;101:4290–7.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Gomez-Sanchez CE, Qi X, Gomez-Sanchez EP, Sasano H, Bohlen MO, Wisgerhof M. Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3. Mol Cell Endocrinol. 2017;439:74–80.CrossRefPubMed Gomez-Sanchez CE, Qi X, Gomez-Sanchez EP, Sasano H, Bohlen MO, Wisgerhof M. Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3. Mol Cell Endocrinol. 2017;439:74–80.CrossRefPubMed
32.
Zurück zum Zitat Nanba K, Omata K, Tomlins SA, Giordano TJ, Hammer GD, Rainey WE, et al. Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. Eur J Endocrinol. 2016;175:K1–6.CrossRefPubMedPubMedCentral Nanba K, Omata K, Tomlins SA, Giordano TJ, Hammer GD, Rainey WE, et al. Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. Eur J Endocrinol. 2016;175:K1–6.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Kuppusamy M, Caroccia B, Stindl J, Bandulik S, Lenzini L, Gioco F, et al. A novel KCNJ5-insT149 somatic mutation close to, but outside, the selectivity filter causes resistant hypertension by loss of selectivity for potassium. J Clin Endocrinol Metab. 2014;99:E1765–73.CrossRefPubMedPubMedCentral Kuppusamy M, Caroccia B, Stindl J, Bandulik S, Lenzini L, Gioco F, et al. A novel KCNJ5-insT149 somatic mutation close to, but outside, the selectivity filter causes resistant hypertension by loss of selectivity for potassium. J Clin Endocrinol Metab. 2014;99:E1765–73.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Zheng FF, Zhu LM, Nie AF, Li XY, Lin JR, Zhang K, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension. 2015;65:622–8.CrossRefPubMed Zheng FF, Zhu LM, Nie AF, Li XY, Lin JR, Zhang K, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension. 2015;65:622–8.CrossRefPubMed
35.
Zurück zum Zitat Scholl UI, Healy JM, Thiel A, Fonseca AL, Brown TC, Kunstman JW, et al. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin Endocrinol. 2015;83:779–89.CrossRef Scholl UI, Healy JM, Thiel A, Fonseca AL, Brown TC, Kunstman JW, et al. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin Endocrinol. 2015;83:779–89.CrossRef
36.
Zurück zum Zitat Nakamura Y, Yamazaki Y, Tezuka Y, Satoh F, Sasano H. Expression of CYP11B2 in aldosterone-producing adrenocortical adenoma: regulatory mechanisms and clinical significance. Tohoku J Exp Med. 2016;240:183–90.CrossRefPubMed Nakamura Y, Yamazaki Y, Tezuka Y, Satoh F, Sasano H. Expression of CYP11B2 in aldosterone-producing adrenocortical adenoma: regulatory mechanisms and clinical significance. Tohoku J Exp Med. 2016;240:183–90.CrossRefPubMed
37.
Zurück zum Zitat Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Somatic and inherited mutations in primary aldosteronism. J Mol Endocrinol. 2017;59:R47–63.CrossRefPubMed Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Somatic and inherited mutations in primary aldosteronism. J Mol Endocrinol. 2017;59:R47–63.CrossRefPubMed
38.
Zurück zum Zitat Pechere-Bertschi A, Herpin D, Lefebvre H. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: medical treatment of primary aldosteronism. Ann Endocrinol (Paris). 2016;77:226–34.CrossRef Pechere-Bertschi A, Herpin D, Lefebvre H. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: medical treatment of primary aldosteronism. Ann Endocrinol (Paris). 2016;77:226–34.CrossRef
39.
Zurück zum Zitat Steichen O, Amar L, Chaffanjon P, Kraimps JL, Menegaux F, Zinzindohoue F. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: adrenal surgery. Ann Endocrinol (Paris). 2016;77:220–5.CrossRef Steichen O, Amar L, Chaffanjon P, Kraimps JL, Menegaux F, Zinzindohoue F. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: adrenal surgery. Ann Endocrinol (Paris). 2016;77:220–5.CrossRef
40.
Zurück zum Zitat He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab. 2013;24:21–30.CrossRefPubMed He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab. 2013;24:21–30.CrossRefPubMed
41.
Zurück zum Zitat Baguet JP, Steichen O, Mounier-Vehier C, Gosse P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris). 2016;77:187–91.CrossRef Baguet JP, Steichen O, Mounier-Vehier C, Gosse P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris). 2016;77:187–91.CrossRef
42.
Zurück zum Zitat Tamargo J, Solini A, Ruilope LM. Comparison of agents that affect aldosterone action. Semin Nephrol. 2014;34:285–306.CrossRefPubMed Tamargo J, Solini A, Ruilope LM. Comparison of agents that affect aldosterone action. Semin Nephrol. 2014;34:285–306.CrossRefPubMed
43.
Zurück zum Zitat Zennaro MC, Caprio M, Feve B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab. 2009;20:444–51.CrossRefPubMed Zennaro MC, Caprio M, Feve B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab. 2009;20:444–51.CrossRefPubMed
44.
Zurück zum Zitat Parviz Y, Iqbal J, Pitt B, Adlam D, Al-Mohammad A, Zannad F. Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends Endocrinol Metab. 2015;26:201–11.CrossRefPubMed Parviz Y, Iqbal J, Pitt B, Adlam D, Al-Mohammad A, Zannad F. Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends Endocrinol Metab. 2015;26:201–11.CrossRefPubMed
Metadaten
Titel
Familial hyperaldosteronism type III a novel case and review of literature
verfasst von
Natividad Pons Fernández
Francisca Moreno
Julia Morata
Ana Moriano
Sara León
Carmen De Mingo
Ángel Zuñiga
Fernando Calvo
Publikationsdatum
19.12.2018
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 1/2019
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-018-9481-0

Weitere Artikel der Ausgabe 1/2019

Reviews in Endocrine and Metabolic Disorders 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.